Abstract
Background
Metformin is an oral medication most commonly prescribed to lower blood glucose levels. However, previous systematic reviews have cast doubt on its effectiveness in reducing the risk of cardiovascular disease (CVD), the costliest side effect of type 2 diabetes mellitus (T2DM).
Objective
This study aimed to combine data from observational studies and randomised controlled trials to determine the impact of metformin on cardiovascular outcomes in diabetic and non-diabetic population.
Methods
On February 24, 2023, a thorough article search was performed in PubMed, EBSCO, Scopus, Web of Science, and ProQuest using keywords and synonyms of Metformin and CVD, coupled with specific terms for different CVDs. Study quality was evaluated using the Cochrane risk of bias tool and Newcastle–Ottawa Scale. Statistical analysis of the data was conducted using R software. PROSPERO registration: CRD42023404151.
Results
A total of 40,087 studies were found through a literature search, of which 22 studies were identified as eligible, involving 612,823 participants, for the meta-analysis. The overall pooled effect estimate for CVD outcome with metformin treatment was found to be a Risk Ratio (RR) of 0.88 (95% CI:0.76-1.03). The pooled effect estimate indicated a significant reduction in CVD-related mortality with metformin treatment, with an RR of 0.75 (95% CI: 0.60-0.93).
Conclusions
This study provides evidence that metformin treatment may not have a significant effect on composite CVD outcomes or individual outcomes such as stroke, MI, HF, and MACE. However, we observed a potential reduction in CVD mortality with metformin use.
Keywords:
Cardiovascular diseases, Diabetes mellitus, Heart failure, Metformin, Myocardial Infarction, Stroke, Angina pectoris, Evidence synthesis, Prevention, Heart attackReferences
Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022;183:109119.
Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalised management. Cardiovascular diabetology. 2022;21(1):74.
Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovascular Diabetology. 2019;18(1):1-16.
Goel S, Singh R, Singh V, et al. Metformin: Activation of 5′ AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. Frontiers in Genetics. 2022;13
Lv Z, Guo Y. Metformin and its benefits for various diseases. Frontiers in endocrinology. 2020;11:191.
Kaur R, Singh V, Kumari P, Singh R, Chopra H, Emran TB. Novel insights on the role of VCAM-1 and ICAM-1: Potential biomarkers for cardiovascular diseases. Annals of Medicine and Surgery. 2022;84:104802.
Shabil M, Bushi G, Beig MA, Rais MA, Ahmed M, Padhi BK. Cardiovascular manifestation in Tuberculosis cases: a Systematic review and Meta-analysis. Current Problems in Cardiology. 2023:101666.
Lee CG, Heckman-Stoddard B, Dabelea D, et al. Effect of metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes care. 2021;44(12):2775-2782.
Filion KB, Douros A, Azoulay L, Yin H, Yu OH, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population‐based cohort study. British Journal of Clinical Pharmacology. 2019;85(10):2378-2389.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. New England journal of medicine. 2008;359(15):1577-1589.
Kim M-H, Oh HJ, Kwon SH, et al. Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study. Kidney Research and Clinical Practice. 2021;40(4):660.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomised clinical trials. Diabetes, Obesity and Metabolism. 2011;13(3):221-228.
Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620-1629.
Xu Z, Zhang H, Wu C, Zheng Y, Jiang J. Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies. Frontiers in Cardiovascular Medicine. 2022;9
Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. American Journal of Cardiology. 2001;88(5):556-557.
Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2019;21(5):1199-1208.
Clegg LE, Jing Y, Penland RC, et al. Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism. 2021;23(5):1101-1110.
Goldberg RB, Orchard TJ, Crandall JP, et al. Effects of long-term metformin and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study. Circulation. 2022;145(22):1632-1641.
Weir DL, Abrahamowicz M, Beauchamp ME, Eurich DT. Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. Diabetes, Obesity and Metabolism. 2018;20(11):2653-2660.
Fonseca V. Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes. Annals of Internal Medicine. 2009;151(4):JC1-12.
Hartman MH, Prins JK, Schurer RA, et al. Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. Clinical Research in Cardiology. 2017;106:939-946.
Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of internal medicine. 2009;169(6):616-625.
Andersson C, Olesen JB, Weeke P, et al. Metformin is Associated With a Low Mortality in Diabetes Patients With Heart Failure. Am Heart Assoc; 2009.
Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomised study. PLoS One. 2008;3(10):e3363.
Bromage DI, Godec TR, Pujades-Rodriguez M, et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology. 2019;18(1):1-9.
Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. The lancet Diabetes & endocrinology. 2014;2(2):116-124.
Ekström N, Schiöler L, Svensson A-M, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open. 2012;2(4):e001076.
Ritsinger V, Lagerqvist B, Lundman P, Hagström E, Norhammar A. Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. Diabetes and Vascular Disease Research. 2020;17(6):1479164120973676.
Fung CSC, Wan EYF, Wong CKH, Jiao F, Chan AKC. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovascular Diabetology. 2015;14(1):1-14.
Wang J, Lu Y, Min X, Yuan T, Wei J, Cai Z. The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: a retrospective study. Frontiers in Cardiovascular Medicine. 2021;8:648212.
Rachmani R, Slavachevski I, Levi Z, Zadok B-S, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. European Journal of Internal Medicine. 2002;13(7):428-433.
Yen F-S, Wei JC-C, Chiu L-T, Hsu C-C, Hwu C-M. Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. Frontiers in Pharmacology. 2022;13
Sillars B, Davis W, Hirsch I, Davis T. Sulphonylurea–metformin combination therapy, cardiovascular disease and all‐cause mortality: the Fremantle Diabetes Study. Diabetes, Obesity and Metabolism. 2010;12(9):757-765.
Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. bmj. 2016;354
Gandhi AP, Satapathy P, Rustagi S, Hermis AH, Sah R, Padhi BK. Comments on” Shigellosis in Southeast Asia: A systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2023 25: 102593-102593
Paridari P, Jabermoradi S, Gholamzadeh R, et al. Can metformin use reduce the risk of stroke in diabetic patients? A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2023;17(2):102721.
Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Research and Clinical Practice. 2020;160:108001.
Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism. 2022 1;130:155160.
Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004 Feb 1;53(2):159-64.
How to Cite
License
Copyright (c) 2023 The Evidence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright© by the author(s). Published by the Evidence Journals. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Most read articles by the same author(s)
- Pawan Kumar, Ahmad Neyazi, Roy Rillera Marzo, Celso Augusto Guimaraes, Joshuan J Barboza, Hashem Abu Serhan, Adnan Kisa, Sarath Lekamwasam, Vasso Apostolopoulos , Alfonso J. Rodríguez-Morales, Ranjit Sah, Mycoplasma pneumoniae returns: understanding its spread and growing impact , The Evidence: Vol. 2 No. 1 (2024): JAN - MAR
- Amaljith A B, Roy Rillera Marzo, Sarath Lekamwasam, Adnan Kisa, Ashish Behera, Preetha S, Praveen Bharath Saravanan, Pankaj B Shah, Subarna Sinha Mahapatra, Gopi Kumbha, Vishaal P, Swathika N. Rama , Noor ul Baddar, Denny Mathew John, Vineeth Rajagopal, Prevalence of fall and its associated factors among elderly population in India: Evidence from the Longitudinal Aging Study of India (LASI) , The Evidence: Vol. 2 No. 2 (2024): APR - JUN
- Ganesh Bushi, Sai Mahesh Vajjala, Furqan B. Irfan, Dipanshu Aggarwal, Safayet Jamil, Drishti Sagar, Alwin Kurian Raju, Mithun Mohan George, Aditi Pal, Preetha S, Ali A. Rabaan, Muhammed Shabil, One health implications of bovine leukemia virus seroprevalence: a global systematic review and meta-analysis , The Evidence: Vol. 2 No. 2 (2024): APR - JUN
- Meenu Singh, Joseph L. Mathew, Ranjit Sah, Celso Augusto Guimarães Santos, Adnan Kisa, Alfonso J. Rodríguez-Morales, Ashish Joshi, Jagdish Khubchandani, Jugal Kishore, Roy Rillera Marzo, Atin Adhikari, Abdulai Abubakari, Aditya Singh, Ahmad Neyazi, Aroop Mohanty, Russell Kabir, Vasso Apostolopoulos, Abhishek Mewara, Aravind P Gandhi, Bijaya K Padhi, Navigating the future of academic publishing: mission and vision of "The Evidence" , The Evidence: Vol. 1 No. 1 (2023): OCT - DEC
